Ravi Kiran Kaja, PhD, explains how USP’s industry-wide initiative aims to build confidence in trace-level extractables and leachables results.
News|Articles|April 1, 2002
- Pharmaceutical Technology-04-02-2002
- Volume 26
- Issue 4
The Usefulness of 0.45 µm–Rated Filter Membranes
In this study, the authors examine the suitability of 0.45 µm–rated filters to be used as sterilizing and bioburden-reduction filters against significant populations of organisms such as B. diminuta in a wide range of differential pressures.
Advertisement
Articles in this issue
over 24 years ago
Outsourcing Outlookover 24 years ago
Monitoring Blend Uniformity with Effusivityover 24 years ago
Bush Budget Combats Bioterrorism, Promotes Drug Safetyover 24 years ago
Liposomes: A ReviewAdvertisement
Related to this article
FDA final guidance defines when companion app output counts as drug labeling and when device-connected or standalone apps belong in prescribing information.
Roche-Hansoh, Merck KGaA-Silence, and Lilly-METiS deals show how ADCs, siRNA, and lipid nanoparticles reshape demands on CMC and manufacturing teams.
AI accountability, faster FDA pathways, rare disease CMC review, and next-gen GLP-1 formulation lead this week’s PharmTech roundup.
Ishani Maharaj of Ingredients + Specialties from Univar Solutions explains how to stabilize GLP-1 multi-agonists, weigh delivery formats, and qualify novel excipients and suppliers.
MASH and cardiomyopathy AI collaboration: AstraZeneca pays insitro $40M upfront for target discovery, then leads clinical development and CMC planning.
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about rare disease treatment development and navigating the FDA’s Rare Pediatric Disease Priority Review Voucher Program.
NVIDIA’s $250M, five-year compute donation funds UK agentic AI safety research, with implications for how GMP teams validate and govern autonomous AI.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
2
Germany’s Medical Biotechnology Sector is Flourishing
3
PharmTech AI Pulse Check: Why Pharma Should Weigh In on FDA's Generative AI Paper
4
AAPS PharmSci 360 2026: System Suitability Standards in E&L Testing
5